|
1) Weatherall DJ. The thalassemias. In: Stamatoyannopoulos G, et al. editors The molecular basis of blood diseases, 3rd ed. Philadelphia: W B Saunders; 2000. p.183-226
|
|
|
|
|
2) Arumugam P, Malik P. Genetic therapy for beta-thalassemia: from the bench to the bedside. Am Soc Hematol Educ Program. 2010; 445-50
|
|
|
|
|
|
3) Papanikolaou E, Anagnou NP. Major challenges for gene therapy of thalassemia and sickle cell disease. Curr Gene Ther. 2010; 10: 404-12
|
|
|
|
|
4) 久米晃啓. 造血幹細胞遺伝子治療後のLMO2, EVI1の活性化. In: 高久史麿, 他編. Annual Review 血液 2011. 東京: 中外医学社; 2011. p.40-7
|
|
|
|
|
|
5) Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalasssaemia. Nature. 2010; 467: 318-22
|
|
|
|
|
|
6) Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001; 294: 2368-71
|
|
|
|
|
|
7) Imren S, Payen E, Westerman KA, et al. Permanent and panerythroid correction of murine β-thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A. 2002; 99: 14380-5
|
|
|
|
|
8) Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002; 296: 2410-3
|
|
|
|
|
|
9) Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12: 401-9
|
|
|
|
|
|
10) Orkin SH, Kazazian HHJr, Antonarakis SE, et al. Abnormal RNA processing due to the exon mutation of βE-globin gene. Nature. 1982; 300: 768-9
|
|
|
|
|
|
11) Sgarra R, Rustighi A, Tessari MA, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett. 2004; 574: 1-8
|
|
|
|
|
|
12) Cleynen I, Van de Ven WJM. The HMGA proteins: a myriad of functions. Int J Oncol. 2008; 32: 289-305
|
|
|
|
|
|
13) Noro B, Licheri B, Sgarra R, et al. Molecular dissection of the architecturial transcription factor HMGA2. Biochemistry. 2003; 42: 4569-77
|
|
|
|
|
|
14) Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell. 2006; 9: 459-71
|
|
|
|
|
|
15) Vallone D, Battista S, Pierantoni GM, et al. Neoplastic transformation of rat thyroid cells erquires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J. 1997; 16: 5310-21
|
|
|
|
|
|
16) Tessari MA, Gostissa M, Altamura S, et al. Transcriptional activation of the cyclin A gene by the architecturial transcription factor HMGA2. Mol Cell Biol. 2003; 23: 9104-6
|
|
|
|
|
|
17) Andrieux J, Bilhou-Nabera C, Lippert E, et al. Expression of HMGA2 in PB leukocytes and purified CD34＋ cells from controls and patients with myelofibrosis and myeloid dysplasia. Leuk Lymphoma. 2006; 47: 1956-9
|
|
|
|
|
|
18) Nishino J, Kim I, Chada K, et al. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf expression. Cell. 2008; 135: 227-39
|
|
|
|
|
|
19) Fedele MS, Battista S, Kenyon L, et al. Over-expression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene. 2002; 21: 3190-8
|
|
|
|
|
|
20) Andrieux J, Demory J-L, Dupriez B, et al. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer. 2004; 39: 82-7
|
|
|
|
|
|
21) Odero MD, Grand FH, Iqbal S, et al. Disruption and aberrant expression of HMGA2 as a conse-quence of diverse chromosomal translocation in myeloid malignancies. Leukemia. 2005; 19: 245-52
|
|
|
|
|
|
22) Hauke S, Flohr AM, Rogalla P, et al. Sequencing of intron 3 of HMGA2 uncovers the existence of a novel exon. Genes Chromosomes Cancer. 2002; 34: 17-23
|
|
|
|
|
|
23) Hauke S, Leopold S, Schlueter C, et al. Extensive expression studies revealed a complex alternative splicing pattern of the HMGA2 gene. Biochem Biophys Acta. 2005; 1729: 24-31
|
|
|
|
|
|
24) 村上良子, 木下タロウ. サラセミアの遺伝子治療が明らかにした造血幹細胞のクローン性増殖メカニズム. 医学のあゆみ. 2011; 237: 233-6
|
|
|
|
|
25) Mayr C, Hemann MT, Bartel BP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007; 315: 1576-9
|
|
|
|
|
|
26) Mayr C, Bartel DP. Widespread shortening of 3ʼUTRs by alternative cleavage and polyadenyla-tion activates oncogenes in cancer cells. Cell. 2009; 138: 673-84
|
|
|
|
|
|
27) Inoue N, Murakami Y, Kinoshita T. Molecular genetics of paroxysmal nocturnal hemo-globinuria. Int J Hematol. 2003; 77: 107-12
|
|
|
|
|
|
28) Inoue N, Izumi-Sarumaru T, Murakami Y, et al. Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006; 108: 4232-6
|
|
|
|
|